🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First panel of the DxA Day focuses on the current diagnostic landscape for Alzheimer’s - from development to implementation, featuring an expert panel les by Nicholas Ashton of Banner Health. CC Oskar Hansson, C2N Diagnostics, WashU Medicine, Beckman Coulter Life Sciences and Biogen

We are thrilled for Dr. Miia Kivipelto, MD, PhD, world-renowned neuroscientist, ADDF Board Member, and Goodes Prize Winner, on her new appointment as the Rodman Family Endowed Professor of Gerontology at Yale Nursing. bit.ly/424FSTT

Jeffrey Cummings gave a fabulous Plenary Lecture at #ADPD25 to introduce his decades efforts on Alzheimer’s Disease Drug Pipeline. It is our great honor to work with him on this important research to advance Alzheimer’s innovation & drug development. 2025 Pipeline comes Alzheimer's Drug Discovery Foundation

Our 8th Annual Memories Matter was a special evening filled with hope and optimism. Thank you to all the ADDF’s friends and supporters who came together at the American Museum of Natural History to support our mission of accelerating the development of drugs to prevent, treat, and cure Alzheimer's.

A new study in Alzheimer’s & Dementia highlights a combination therapy (QuadRx) that slowed cognitive decline by 47% in one dataset and by 60% in another over 10 years for individuals with Alzheimer’s. bit.ly/428BJNd

Exciting news in the development of noninvasive therapies from our funded investigator Giacomo Koch, MD, PhD and the novel transcranial magnetic stimulation (rTMS) device from Sinaptica Therapeutics successfully met its primary endpoint in a phase 2 clinical trial. bit.ly/3Y3w4qL

This week, Dr. Roberta Diaz Brinton, a leader in Alzheimer’s research and recipient of the Goodes Prize, discussed with the The New York Times her promising work using allopregnanolone, as a regenerative therapy for individuals with Alzheimer’s. nytimes.com/2025/04/22/hea…

ADDF’s Diagnostics Accelerator (DxA) announced a new investment to support the AI version of MoCA Cognition, MoCA Solo. This digital diagnostic tool enables early detection of Alzheimer’s, underscoring our commitment to accurate cognitive testing. bit.ly/3EPLfNC

The ADDF and Harrington Discovery Institute are pleased to announce a joint RFP for the 2026 ADDF-Harrington Scholar Award, aimed at accelerating the translation of innovative research that may treat, prevent, slow, or reverse Alzheimer's or related dementias. bit.ly/2rEQkiv

ADDF’s Diagnostics Accelerator (DxA) announced a new partnership with Siemens Healthineers to license SpeechDx, a gold standard dataset for Alzheimer’s biomarker, which accelerates the development of digital diagnostics & potential for earlier detection. bit.ly/43k2YFt

A new survey reveals 79% of Americans aged 45+ want to know if they're in the early stages of Alzheimer's. With new blood tests and treatments available, more are opting for early diagnosis and proactive care. Jon Hamilton Alzheimer's Association NPR n.pr/3EQwOcg

Anti-aging drugs like Metformin may target various mechanisms that benefit diseases like Alzheimer's. Dr. Nir Barzilai and Goodes Prize winner Miia Kivipelto are researching prevention methods for healthy aging while maintaining cognitive function. nyti.ms/4iJMSuj

Lifestyle changes may reduce up to 40% of dementia cases, according to the FINGER trial led by Dr. Miia Kivipelto, highlighting the importance of lifestyle intervention and the next generation of combination therapies in Alzheimer’s prevention. bit.ly/3GUgIih

Dr. Jeffrey Cummings, renowned Alzheimer’s researcher at @UNLV, is advancing new treatments with projects like the ADDF-funded biomarker observatory, the first comprehensive overview of the Alzheimer’s biomarkers pipeline to accelerate drug development. bit.ly/4iTY

The 15th Annual Great Ladies Luncheon Sparkles at the Ritz Carlton thewashingtonlobbyist.com/the-15th-annua… Alzheimer's Drug Discovery Foundation

Fantastic conversation with Hannah Kuchler and Laura Steele of Eli Lilly and Company at the Financial Times’s US Pharma and Biotech Summit on the current and future Alzheimer’s treatment landscape, which will eventually lie in a combination therapy and precision medicine approach. #FTpharma

ADDF-funded company, Life Molecular Imaging, announced the development of [18F]F DED, a new PET imaging agent designed to target a key enzyme linked to neuroinflammation in the brain and will deepen our understanding of the disease’s underlying biology. bit.ly/3ZmMGtY

Our 15th Annual Great Ladies Luncheon & Fashion Show celebrated science & style! We honored Dr. Howard Fillit for his leadership in Alzheimer’s research and Eisai US for advancing the drug development and transformative treatments of Aricept and Lecanemab (Leqembi).

Today marks a major milestone in Alzheimer’s with the FDA approval of the first blood test for Alzheimer's from @fujirebio. Funded in part by the Diagnostics Accelerator, this test will bring faster, more accessible diagnosis into mainstream care: bit.ly/4jZTxlF.

A big step forward in the fight against Alzheimer’s: The FDA approved the first blood test to help diagnose the disease. Breakthroughs like this will make earlier, easier diagnosis possible—bringing us closer to better treatments and, someday, a cure. b-gat.es/4jaHGjm